The membrane-proximal kxgffkr motif of α-integrin mediates chemoresistance

Molecular and Cellular Biology

Volumn 33, Issue 21, 2013, Pages 4334-4345

  Liu, Chi Chao ^a,b,c   Leclair, Pascal ^a,c   Yap, Shyong Quin ^a,c   Lim, Chinten James ^a,c  

^a Department of Pediatrics ^*  (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTEGRIN; BETA1 INTEGRIN; CALCIUM ION; CALRETICULIN; DOXORUBICIN; PEPTIDES AND PROTEINS; PROTEIN TACDELTA; UNCLASSIFIED DRUG; VERAPAMIL;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL MEMBRANE; DRUG RESISTANCE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AMINO ACID SEQUENCE; ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, CD29; APOPTOSIS; CALCIUM CHANNELS, L-TYPE; CALCIUM SIGNALING; CALRETICULIN; CELL ADHESION; CELL SURVIVAL; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; HUMANS; INTEGRIN ALPHA4; INTEGRIN ALPHA5; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; JURKAT CELLS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84886920345     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00580-13     Document Type: Article

References (58)

1. Estey E, Dohner H. 2006. Acute myeloid leukaemia. Lancet 368:1894-1907.
2. Pui CH, Evans WE. 2006. Treatment of acute lymphoblastic leukemia. N. Engl. J. Med. 354:166-178.
3. Matsunaga T, Takemoto N, Sato T, Takimoto R, Tanaka I, Fujimi A, Akiyama T, Kuroda H, Kawano Y, Kobune M, Kato J, Hirayama Y, Sakamaki S, Kohda K, Miyake K, Niitsu Y. 2003. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat. Med. 9:1158-1165.
4. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. 1999. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 93:1658-1667.
5. Matsunaga T, Fukai F, Miura S, Nakane Y, Owaki T, Kodama H, Tanaka M, Nagaya T, Takimoto R, Takayama T, Niitsu Y. 2008. Combination therapy of an anticancer drug with the FNIII14 peptide of fibronectin effectively overcomes cell adhesion-mediated drug resistance of acute myelogenous leukemia. Leukemia 22:353-360.
6. Damiano JS, Hazlehurst LA, Dalton WS. 2001. Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and gamma-irradiation. Leukemia 15:1232-1239.
7. De Toni-Costes F, Despeaux M, Bertrand J, Bourogaa E, Ysebaert L, Payrastre B, Racaud-Sultan C. 2010. A new α5β1 integrin-dependent survival pathway through GSK3β activation in leukemic cells. PLoS One 5(3):e9807. doi:10.1371/journal.pone.0009807.
8. Yamakawa N, Kaneda K, Saito Y, Ichihara E, Morishita K. 2012. The increased expression of integrin α6 (ITGA6) enhances drug resistance in EVI1high leukemia. PLoS One 7(1):e30706. doi:10.1371/journal.pone.0030706.
9. Mudry RE, Fortney JE, York T, Hall BM, Gibson LF. 2000. Stromal cells regulate survival of B-lineage leukemic cells during chemotherapy. Blood 96:1926-1932.
10. Meads MB, Gatenby RA, Dalton WS. 2009. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat. Rev. Cancer 9:665-674.
11. Abram CL, Lowell CA. 2009. The ins and outs of leukocyte integrin signaling. Annu. Rev. Immunol. 27:339-362.
12. Hynes RO. 2002. Integrins: bidirectional, allosteric signaling machines. Cell 110:673-687.
13. Rose DM, Han J, Ginsberg MH. 2002. α4 integrins and the immune response. Immunol. Rev. 186:118-124.
14. Mraz M, Zent CS, Church AK, Jelinek DF, Wu X, Pospisilova S, Ansell SM, Novak AJ, Kay NE, Witzig TE, Nowakowski GS. 2011. Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin alpha-4-beta-1 (VLA-4) with natalizumab can overcome this resistance. Br. J. Haematol. 155:53-64.
15. Kurtova AV, Tamayo AT, Ford RJ, Burger JA. 2009. Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. Blood 113:4604-4613.
16. Rettig MP, Ansstas G, DiPersio JF. 2012. Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4. Leukemia 26:34-53.
17. Naci D, El Azreq MA, Chetoui N, Lauden L, Sigaux F, Charron D, Al-Daccak R, Aoudjit F. 2012. α2β1 integrin promotes chemoresistance against doxorubicin in cancer cells through extracellular signal-regulated kinase (ERK). J. Biol. Chem. 287:17065-17076.
18. King WG, Mattaliano MD, Chan TO, Tsichlis PN, Brugge JS. 1997. Phosphatidylinositol 3-kinase is required for integrin-stimulated AKT and Raf-1/mitogen-activated protein kinase pathway activation. Mol. Cell. Biol. 17:4406-4418.
19. Aoudjit F, Vuori K. 2012. Integrin signaling in cancer cell survival and chemoresistance. Chemother. Res. Pract. 2012:283181. doi:10.1155/2012/283181.
20. Kassner PD, Kawaguchi S, Hemler ME. 1994. Minimum alpha chain cytoplasmic tail sequence needed to support integrin-mediated adhesion. J. Biol. Chem. 269:19859-19867.
21. Rantala JK, Pouwels J, Pellinen T, Veltel S, Laasola P, Mattila E, Potter CS, Duffy T, Sundberg JP, Kallioniemi O, Askari JA, Humphries MJ, Parsons M, Salmi M, Ivaska J. 2011. SHARPIN is an endogenous inhibitor of β1-integrin activation. Nat. Cell Biol. 13:1315-1324.
22. Nevo J, Mai A, Tuomi S, Pellinen T, Pentikainen OT, Heikkila P, Lundin J, Joensuu H, Bono P, Ivaska J. 2010. Mammary-derived growth inhibitor (MDGI) interacts with integrin alpha-subunits and suppresses integrin activity and invasion. Oncogene 29:6452-6463.
23. Knoblauch A, Will C, Goncharenko G, Ludwig S, Wixler V. 2007. The binding of Mss4 to alpha-integrin subunits regulates matrix metalloproteinase activation and fibronectin remodeling. FASEB J. 21:497-510.
24. Barry WT, Boudignon-Proudhon C, Shock DD, McFadden A, Weiss JM, Sondek J, Parise LV. 2002. Molecular basis of CIB binding to the integrin alpha IIb cytoplasmic domain. J. Biol. Chem. 277:28877-28883.
25. Coppolino MG, Woodside MJ, Demaurex N, Grinstein S, St-Arnaud R, Dedhar S. 1997. Calreticulin is essential for integrin-mediated calcium signalling and cell adhesion. Nature 386:843-847.
26. Nishiya N, Kiosses WB, Han J, Ginsberg MH. 2005. An α4 integrinpaxillin- Arf-GAP complex restricts Rac activation to the leading edge of migrating cells. Nat. Cell Biol. 7:343-352.
27. Lim CJ, Han J, YousefiN, Ma Y, Amieux PS, McKnight GS, Taylor SS, Ginsberg MH. 2007. α4 integrins are type I cAMP-dependent protein kinase-anchoring proteins. Nat. Cell Biol. 9:415-421.
28. Rivera Rosado LA, Horn TA, McGrath SC, Cotter RJ, Yang JT. 2011. Association between α4 integrin cytoplasmic tail and non-muscle myosin IIA regulates cell migration. J. Cell Sci. 124:483-492.
29. Rose DM, Liu S, Woodside DG, Han J, Schlaepfer DD, Ginsberg MH. 2003. Paxillin binding to the alpha 4 integrin subunit stimulates LFA-1 (integrin alpha L beta 2)-dependent T cell migration by augmenting the activation of focal adhesion kinase/proline-rich tyrosine kinase-2. J. Immunol. 170:5912-5918.
30. Jongewaard IN, Tsai PM, Smith JW. 1996. The type III connecting segment of fibronectin contains an aspartic acid residue that regulates the rate of binding to integrin alpha 4 beta 1. Cell Adhes. Commun. 3:487-495.
31. Ramos JW, DeSimone DW. 1996. Xenopus embryonic cell adhesion to fibronectin: position-specific activation of RGD/synergy site-dependent migratory behavior at gastrulation. J. Cell Biol. 134:227-240.
32. Liu S, Thomas SM, Woodside DG, Rose DM, Kiosses WB, PfaffM, Ginsberg MH. 1999. Binding of paxillin to α4 integrins modifies integrindependent biological responses. Nature 402:676-681.
33. Bodeau AL, Berrier AL, Mastrangelo AM, Martinez R, LaFlamme SE. 2001. A functional comparison of mutations in integrin beta cytoplasmic domains: effects on the regulation of tyrosine phosphorylation, cell spreading, cell attachment and β1 integrin conformation. J. Cell Sci. 114: 2795-2807.
34. Song G, Ouyang G, Bao S. 2005. The activation of Akt/PKB signaling pathway and cell survival. J. Cell. Mol. Med. 9:59-71.
35. Weismann M, Guse AH, Sorokin L, Broker B, Frieser M, Hallmann R, Mayr GW. 1997. Integrin-mediated intracellular Ca2+ signaling in Jurkat T lymphocytes. J. Immunol. 158:1618-1627.
36. Xia CQ, Smith PG. 2012. Drug efflux transporters and multidrug resistance in acute leukemia: therapeutic impact and novel approaches to mediation. Mol. Pharmacol. 82:1008-1021.
37. El Azreq MA, Naci D, Aoudjit F. 2012. Collagen/β1 integrin signaling up-regulates the ABCC1/MRP-1 transporter in an ERK/MAPKdependent manner. Mol. Biol. Cell 23:3473-3484.
38. Homolya L, Hollo Z, Germann UA, Pastan I, Gottesman MM, Sarkadi B. 1993. Fluorescent cellular indicators are extruded by the multidrug resistance protein. J. Biol. Chem. 268:21493-21496.
39. Nakamura K, Bossy-Wetzel E, Burns K, Fadel MP, Lozyk M, Goping IS, Opas M, Bleackley RC, Green DR, Michalak M. 2000. Changes in endoplasmic reticulum luminal environment affect cell sensitivity to apoptosis. J. Cell Biol. 150:731-740.
40. Goicoechea S, Orr AW, Pallero MA, Eggleton P, Murphy-Ullrich JE. 2000. Thrombospondin mediates focal adhesion disassembly through interactions with cell surface calreticulin. J. Biol. Chem. 275:36358-36368.
41. Kwon MS, Park CS, Choi K, Ahnn J, Kim JI, Eom SH, Kaufman SJ, Song WK. 2000. Calreticulin couples calcium release and calcium influx in integrin-mediated calcium signaling. Mol. Biol. Cell 11:1433-1443.
42. Coppolino M, Leung-Hagesteijn C, Dedhar S, Wilkins J. 1995. Inducible interaction of integrin alpha 2 beta 1 with calreticulin. Dependence on the activation state of the integrin. J. Biol. Chem. 270:23132-23138.
43. Coppolino MG, Dedhar S. 1999. Ligand-specific, transient interaction between integrins and calreticulin during cell adhesion to extracellular matrix proteins is dependent upon phosphorylation/dephosphorylation events. Biochem. J. 340:41-50.
44. de la Fuente MT, Casanova B, Moyano JV, Garcia-Gila M, Sanz L, Garcia-Marco J, Silva A, Garcia-Pardo A. 2002. Engagement of α4β1 integrin by fibronectin induces in vitro resistance of B chronic lymphocytic leukemia cells to fludarabine. J. Leukoc. Biol. 71:495-502.
45. Gattei V, Bulian P, Del Principe MI, Zucchetto A, Maurillo L, Buccisano F, Bomben R, Dal-Bo M, Luciano F, Rossi FM, Degan M, Amadori S, Del Poeta G. 2008. Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Blood 111:865-873.
46. Vincent EE, Elder DJ, Thomas EC, Phillips L, Morgan C, Pawade J, Sohail M, May MT, Hetzel MR, Tavare JM. 2011. Akt phosphorylation on Thr308 but not on Ser473 correlates with Akt protein kinase activity in human non-small cell lung cancer. Br. J. Cancer 104:1755-1761.
47. Gallay N, Dos Santos C, Cuzin L, Bousquet M, Simmonet Gouy V, Chaussade C, Attal M, Payrastre B, Demur C, Recher C. 2009. The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia. Leukemia 23:1029-1038.
48. Yano S, Tokumitsu H, Soderling TR. 1998. Calcium promotes cell survival through CaM-K kinase activation of the protein-kinase-B pathway. Nature 396:584-587.
49. Vanhaesebroeck B, Alessi DR. 2000. The PI3K-PDK1 connection: more than just a road to PKB. Biochem. J. 346:561-576.
50. Wu X, Davis GE, Meininger GA, Wilson E, Davis MJ. 2001. Regulation of the L-type calcium channel by alpha 5 beta 1 integrin requires signaling between focal adhesion proteins. J. Biol. Chem. 276:30285-30292.
51. Sulova Z, Seres M, Barancik M, Gibalova L, Uhrik B, Polekova L, Breier A. 2009. Does any relationship exist between P-glycoprotein-mediated multidrug resistance and intracellular calcium homeostasis. Gen. Physiol. Biophys. 28(Focus Iss):F89-F95.
52. Michalak M, Groenendyk J, Szabo E, Gold LI, Opas M. 2009. Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum. Biochem. J. 417:651-666.
53. Tran H, Pankov R, Tran SD, Hampton B, Burgess WH, Yamada KM. 2002. Integrin clustering induces kinectin accumulation. J. Cell Sci. 115: 2031-2040.
54. Zhu Q, Zelinka P, White T, Tanzer ML. 1997. Calreticulin-integrin bidirectional signaling complex. Biochem. Biophys. Res. Commun. 232: 354-358.
55. Gold LI, Eggleton P, Sweetwyne MT, Van Duyn LB, Greives MR, Naylor SM, Michalak M, Murphy-Ullrich JE. 2010. Calreticulin: nonendoplasmic reticulum functions in physiology and disease. FASEB J. 24: 665-683.
56. Afshar N, Black BE, Paschal BM. 2005. Retrotranslocation of the chaperone calreticulin from the endoplasmic reticulum lumen to the cytosol. Mol. Cell. Biol. 25:8844-8853.
57. Shaffer KL, Sharma A, Snapp EL, Hegde RS. 2005. Regulation of protein compartmentalization expands the diversity of protein function. Dev. Cell 9:545-554.
58. Kim C, Ye F, Ginsberg MH. 2011. Regulation of integrin activation. Annu. Rev. Cell Dev. Biol. 27:321-345.